CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production

Rajula Gaur†, Kofi A. Mensah†, Jason Stricker, Mary Adams, Anastasia Parton, Dorota Cedzik, Jamie Connarn, Michael Thomas, Gerald Horan, Peter Schaefer, Stuart Mair, Maria Palmisano and Francisco Ramírez-Valle*

Abstract

Background: Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibitor under development for the treatment of ankylosing spondylitis (AS) and other inflammatory diseases. As part of a phase I clinical trial to assess safety and tolerability, we evaluated target engagement, pharmacokinetics, and pharmacodynamics of CC-99677.

Methods: The MK2 inhibitor CC-99677 was evaluated for its effect on cytokine expression in vitro in peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with a definitive AS diagnosis. A novel in vitro model was developed to compare the potential for tachyphylaxis of CC-99677 and p38 inhibitors in THP-1 cells. The effect of CC-99677 on tristetraprolin (TTP) and cytokine mRNA was assessed in stimulated human monocyte-derived macrophages. In a first-in-human study, thirty-seven healthy volunteers were randomly assigned to daily oral doses of CC-99677 or placebo, and blood was collected at pre-specified time points before and after dosing. CC-99677 concentrations were assessed in the plasma, and CC-99677 binding to MK2 was evaluated in PBMCs. Ex vivo stimulation of the whole blood was conducted from participants in the first-in-human study to assess the pharmacodynamic effects.

Results: In vitro, CC-99677 inhibited tumor necrosis factor (TNF), interleukin (IL)-6, and IL-17 protein production in samples of monocytes and macrophages from AS patients and healthy volunteers via an mRNA-destabilization mechanism. In the in vitro model of tachyphylaxis, CC-99677 showed a differentiated pattern of sustained TNF protein inhibition compared with p38 inhibitors. CC-99677 reduced TTP phosphorylation and accelerated the decay of inflammatory cytokine mRNA in lipopolysaccharide-stimulated macrophages. Administration of CC-99677 to healthy volunteers was safe and well-tolerated, with linear pharmacokinetics and sustained reduction of ex vivo whole blood TNF, IL-6, and chemokine synthesis.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Spondyloarthritis comprises a group of inflammatory rheumatic diseases that is characterized by spinal and peripheral joint oligoarthritis and enthesitis and may be associated with mucocutaneous, ocular, and/or cardiac comorbidities [1]. Treatment for these diseases consists of nonsteroidal anti-inflammatory drugs as the first line of therapy, with biologic agents targeting cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-17, considered for patients who do not respond [2]. Although TNF and IL-17 inhibitors have demonstrated improved disease-related parameters in patients with ankylosing spondylitis (AS), the effects on radiographic progression are less well defined [3, 4]. Therefore, an unmet need exists for new treatments that address both disease-related parameters and radiographic progression.

The p38–mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the stress-mediated production of proinflammatory cytokines (TNF, IL-6, and IL-1β), and inhibitors of p38-MAPK have been extensively investigated for the treatment of inflammatory diseases [5–7]. p38-MAPK has nearly one hundred known substrates, including kinases, transcriptional factors and regulators, cell cycle regulators, and other MAPKs [8]. Inhibitors of p38-MAPK with autoimmune disease-related indications have failed to advance in clinical development, due to hepatotoxicity, cardiotoxicity, and lack of efficacy [5, 7, 9, 10].

p38-MAPK inhibitors have been associated with tachyphylaxis in patients with rheumatoid arthritis and other inflammatory diseases, in which early reduction in inflammatory markers such as C-reactive protein (CRP) did not persist despite continued treatment [5, 9, 11]. The observation of tachyphylaxis may be explained by the pleiotropic role of p38, and inhibition of p38-MAPK may result in the activation of compensatory mechanisms. For instance, p38 inhibition has been observed to activate the upstream kinases MAPK kinase 4 and 7 (MKK4/7) and inhibit the negative MAPK regulator dual-specificity phosphatase 1 (DUSP1), which inhibits multiple MAPKs including p38-MAPK [12, 13]. Therefore, as a means to avoid the observed limitations inherent in targeting p38-MAPK, proteins downstream of p38-MAPK have been identified as new targets for inflammatory diseases.

MAPK-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising target for inflammatory diseases. Activation of MK2 increases the stability and translation of mRNA of proinflammatory factors (e.g., TNF, IL-1β, IL-6) [14–16]. The effect of MK2 at the post-transcriptional level is mediated by tristetraprolin (TTP), a zinc finger binding protein that binds to the AU-rich elements (ARE) in the 3′ untranslated regions (UTRs) [17]. Through the recruitment of deadenylases, TTP destabilizes the mRNA of multiple cytokines containing ARE in their 3′UTRs, including TNF, GM-CSF, IL-10, IL-6, and also its own mRNA, resulting in an auto-regulatory negative feedback loop [18–20]. Human antigen R (HuR), an RNA-stabilizing protein, plays an opposing role to TTP by competing for binding to the ARE and promoting translation. Activated MK2 phosphorylates TTP and reduces its affinity to ARE, thereby allowing HuR to bind and promote cytokine production by stabilizing mRNA and enhancing translation [17]. MK2 knockout mice, unable to stabilize transcripts of pro-inflammatory cytokines via TTP, are protected from inflammation in various inflammatory disease models [15, 21]. MK2 inhibitors have demonstrated efficacy in models of arthritis and AS [21–23].

Here, we describe in vitro studies using peripheral blood mononuclear cells (PBMCs) from AS patients and healthy volunteers to analyze the effect of CC-99677 on proinflammatory proteins. To delineate the mechanism of action of CC-99677 on cytokine production, we investigated its effect on TTP phosphorylation and on cytokine mRNA decay in macrophages. We explore the relationship between drug exposure and tachyphylaxis potential in a novel in vitro assay in THP-1 cells and contrast CC-99677 activity with activity of p38 inhibitors. We also report data from the phase I first-in-human (FIH) multiple ascending-dose (MAD) study to characterize the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CC-99677 in healthy volunteers treated with CC-99677; single ascending-dose data are reported elsewhere [23, 24].

Methods
Culturing PBMCs from healthy and AS patient samples
Human PBMCs from healthy volunteers and patients with AS from Bio-Options (Brea, CA) were thawed

Conclusions: CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases and may overcome the limitations of p38 MAPK inhibition.

Trial registration: ClinicalTrials.gov NCT03554993.

Keywords: Spondyloarthritis, Inflammatory arthritis, Mitogen-activated protein kinase kinases, Cytokines, Immunology, Clinical pharmacology
and washed with phosphate-buffered saline (PBS). For lipopolysaccharide (LPS) stimulation, RPMI 1640 medium, supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin, was used to culture cells. Cells were pretreated with dimethyl sulfoxide (DMSO; 0.25%) or CC-99677 at 0.3, 1, and 3 μM for 1 h followed by LPS at 50 ng/mL for 24 h. In the case of Staphylococcal enterotoxin-B (SEB)/IL-2 treatment, cells were cultured in RPMI 1640 medium, supplemented with 10% FBS, 1% GlutaMAX, and 1% HEPES and penicillin/streptomycin, for 3 days. All cells were cultured at 37 °C with 5% CO2 in a humidified incubator. The culture media were harvested and frozen for cytokine and chemokine assessment.

Daily treatment of THP-1 cells with CC-99677 or p38 inhibitors
THP-1 cells were seeded at 1.0 × 10⁶ cells/mL and allowed to acclimate for 24 h. Cell count and viability were measured daily to monitor cell number and health. To maintain the cell populations around 1.0 × 10⁶ cells/mL, cells were split every other day. p38 inhibitors (BMS-582949, BIRB-796, and SCIO-469), MK2 inhibitor CC-99677, or DMSO were added daily to maintain constant exposure until the time of sample collection. Samples were collected on days 0, 1, 3, 6, 9, 12, and 14. At each time point, the cells were stimulated with 100 ng/mL LPS for 24 h, to mimic the ex vivo assay that is performed in the clinic, and TNF levels were measured in the supernatants using enzyme-linked immunosorbent assay (ELISA; cat. no. 18421, Abcam, Cambridge, MA).

Cytokine analysis by ELISA
Culture supernatants were centrifuged, and the supernatants were collected and analyzed for selected cytokines and chemokines using Milliplex Magpix assays (catalog HCYTO – 60K; Millipore Sigma, Burlington, MA). Levels of proinflammatory cytokines TNF and MCP-1 for the monocytes and macrophages were quantified using specific ELISA kits (R&D, NJ, USA) according to the manufacturer’s recommendations. Data were processed using Milliplex Analyst, and significance was calculated using the one-way analysis of variance (ANOVA) with Dunnett’s post-test algorithms in GraphPad Prism version 5.01.

Assessing mRNA stability in macrophages
Monocytes differentiated into macrophages with M-CSF and IFNγ were stimulated with LPS for 3 h followed by treatment with 10 μg/mL actinomycin D in the presence of 1 μM CC-99677 or DMSO for 0 h, 10 min, 30 min, and 1, 2, 4, 5, and 6 h at 37 °C. After each time point, macrophages were washed with PBS and lysed with RLT Plus Lysis Buffer (Qiagen, Germantown, MD). RNA was isolated using the QiaCube, followed by cDNA preparation using Superscript IV enzyme mix (Invitrogen, Thermo Fisher, Waltham, MA). Rate of mRNA decay by actinomycin D and CC-99677 was monitored by reverse transcription polymerase chain reaction with human primers against TNF, IL-6, and IL-1β using GAPDH as a housekeeping gene.

Clinical study design
A single-center, randomized, double-blind, placebo-controlled phase I study (NCT03554993) with a MAD component was performed in the UK between May 2018 and July 2019. Thirty-seven healthy volunteers of any race, ethnicity, or sex were enrolled. The inclusion criteria were 18 to 55 years of age inclusive, body mass index 18 to 33 kg/m², and physical examination by the investigator without clinically significant findings. Subjects were excluded if any clinically significant medical history, laboratory abnormality, psychiatric illness, or other condition existed that would place the subject at unacceptable risk by participating in the study. Pregnancy prevention guidance was provided as per Clinical Trial Facilitation Group recommendations [25]. Subjects were randomly assigned to daily oral doses of CC-99677 or placebo. Subjects were dosed daily for 14 days. There were 5 dose-escalation

Assessing the effect of CC-99677 on cytokines and TTP
Monocytes and macrophages were pre-treated for 1 h with DMSO or compound, followed by LPS stimulation (100 ng/mL) for 4 or 24 h (includes 1 h pre-treatment). Medium from the cultured macrophages was used for cytokine analysis using Magpix magnetic beads (Catalog HCYTO – 60K; Millipore Sigma, Burlington, MA). Cell pellets from the macrophage cultures were collected for western blot analysis using capillary electrophoresis to analyze the effect on TTP with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) used as the house-keeping protein in the capillary electrophoresis. Antibodies against total TTP (CST#7162 Rabbit Monoclonal antibody) and GAPDH (CST#5174 Rabbit Monoclonal antibody) were used to detect the respective proteins.

Differentiating human monocytes into macrophages
PBMCs were isolated from buffy coat using the Ficoll gradient method. Monocytes were isolated using the STEMCELL Technologies Inc. kit (catalog number 19058; Vancouver, BC, Canada). Monocytes were differentiated into macrophages by stimulating with 50 ng/mL of macrophage colony-stimulating factor (M-CSF) for 5 days followed by treatment with 50 ng/mL interferon gamma (IFNγ) for ~ 16 h. Macrophages were then plated and allowed to acclimate for 24 h.
cohorts ranging from 10 to 150 mg of CC-99677 or placebo. Both the investigator and subjects were blinded to the treatment arm. Safety assessments, including physical examinations, clinical laboratory tests, and collection of adverse events (AEs) were performed and graded using MedDRA version 22.0 and the US Food and Drug Administration (FDA) Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers [26]. The primary outcome of this trial was the safety and tolerability of multiple daily doses of CC-99677. Secondary and exploratory outcomes included assessment of the PK profile and evaluation of the PD effects of CC-99677 as measured by MK2 occupancy and ex vivo inhibition of inflammatory cytokines.

Target engagement assay
Target engagement of MK2 was measured using the streptavidin mass shift (SMaSh) assay in PBMCs, which is designed to indicate amounts of MK2 occupied and unoccupied by covalently bound CC-99677 [23, 27]. Blood was collected for PBMC isolation at pre-specified time points, before dosing on days 1, 2, 3, 5, 7, and 14 and then following the last dose on days 15, 17, 21, and 28. Samples were evaluated for the percentage of MK2 bound to CC-99677 versus the percentage of free MK2 in PBMCs under the indicated cohort dosage conditions. Target engagement was measured by calculating the change in percentage bound MK2 from baseline.

Pharmacokinetic assessment
Blood was collected for the determination of CC-99677 plasma concentrations at pre-specified time points for intense PK sampling. Concentrations of CC-99677 in the plasma were measured using a validated liquid chromatography tandem mass spectrometry assay. PK parameters were calculated via non-compartmental methodology using Phoenix version 7 or higher (Princeton, NJ).

Pharmacodynamic assessment
Effects of CC-99677 on innate cell activities were evaluated by assessing cytokine and chemokine production following LPS stimulation ex vivo. Ex vivo stimulation was performed in whole blood samples collected before dosing on days 1, 2, 3, 5, 7, and 14 and then following the last dose on days 15, 17, 21, and 28 using the TruCulture® assay system (Myriad RBM, Austin, TX). Briefly, blood (1 mL) was drawn into the LPS-containing TruCulture tubes. The tubes were placed in a 37 °C block thermostat for 24 ± 1 h and then frozen at −70 °C. Media mixed with plasma were analyzed for TNF and other cytokine/chemokine levels. TNF inhibition in ex vivo LPS-stimulated blood was measured as a percentage change in TNF levels from baseline. Percentage change in other cytokines and chemokines in the ex vivo stimulation assay was also measured with respect to their baseline levels.

Results
CC-99677 inhibited cytokine production in PBMCs from patients with AS
We have previously shown that CC-99677 inhibits inflammatory cytokine production from LPS-stimulated healthy donor PBMCs, including TNF, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) [23]. We investigated the effect of CC-99677 in AS patient samples and observed a similar concentration-dependent inhibition of TNF production in LPS-stimulated PBMCs (Fig. 1A). Because GM-CSF may prime PBMCs and monocytes from patients with AS for increased TNF production, we also determined the effect of CC-99677 on GM-CSF expression in PBMCs from both healthy donors and AS patients (Fig. 2).

MK2 inhibition reduced cytokine production in LPS-stimulated monocytes and macrophages
Myeloid cells such as monocytes are critical producers of TNF, IL-23, and other inflammatory cytokines in AS [30, 31]. Given their key pro-inflammatory roles, we sought to determine the effect of CC-99677 on LPS-stimulated monocytes and macrophages. Macrophages were derived from monocytes and differentiated into pro-inflammatory M1 type by M-CSF treatment followed by IFNγ. CC-99677 exhibited strong concentration-dependent inhibition of TNF in both monocytes and macrophages (Fig. 3A). CC-99677 also exhibited concentration-dependent inhibition of IL-6 and IL-1β secretion in monocytes and macrophages, although the inhibitory effects of CC-99677 on cytokine secretion were more potent in macrophages (Fig. 3A).

CC-99677 prevented TTP phosphorylation to promote cytokine mRNA decay
To confirm the mechanism of cytokine inhibition downstream of MK2 inhibition, we evaluated the effect of CC-99677 on the TTP phosphorylation state and cytokine mRNA stability. We used an antibody against TTP to investigate the effect on protein levels by capillary
electrophoresis. Although phospho-TTP-specific antibodies are not available, total TTP protein levels can be used as a surrogate for the TTP phosphorylation state. The stability and total abundance of TTP are regulated by its phosphorylation by MK2: when TTP is dephosphorylated, it becomes unstable and therefore total TTP protein levels are reduced [20]. As expected, LPS stimulation in macrophages resulted in TTP phosphorylation reflected by increased TTP abundance (Fig. 3B). Notably, CC-99677 treatment resulted in a dose-dependent reduction in total TTP levels, indicating a reduced phosphorylation state. We then assessed the effect of CC-99677 inhibition of TTP phosphorylation on cytokine mRNA stability. The mRNA decay of ARE-containing TNF, IL-6, and IL-1β transcripts was measured in LPS-stimulated macrophages in the presence of actinomycin D alone and in combination with CC-99677. The expression of each pro-inflammatory gene transcript was normalized to GAPDH mRNA. A decrease in cytokine mRNA levels was observed with actinomycin D alone over time; however, the combination of actinomycin D and CC-99677 resulted in significantly greater mRNA decay compared with actinomycin D alone (Fig. 3C).

**Sustained in vitro TNF inhibition by CC-99677 but not by p38 inhibitors**

In clinical studies with p38 inhibitors, early reduction in proinflammatory markers such as CRP was not sustained over the treatment period. Inflammatory marker levels were found to rebound as early as 2 weeks after
treatment, suggesting tachyphylaxis [5, 7, 9, 10]. We sought to develop a model of continued inhibitor treatment to determine the potential for tachyphylaxis in vitro. THP-1 cells were treated daily with p38 inhibitors or CC-99677 for up to 14 days. At different times during this treatment period, an aliquot of cells was stimulated with LPS. As expected, at early times during the treatment period, p38 inhibitors blocked LPS-stimulated TNF production (Fig. 4). However, beginning on day 9, loss of TNF inhibitory effect was noted for all p38 inhibitors tested (BMS-582949, BIRB-796, SCIO-469). In contrast to p38 inhibitors, CC-99677 suppressed TNF production throughout the treatment period. These data suggest that MK2 inhibition may circumvent tachyphylaxis associated with p38 inhibitors.

CC-99677 was safe and well-tolerated in a multiple ascending dose study

The effects of CC-99677 in vitro and in vivo supported the initiation of a FIH clinical study in healthy volunteers [23]. The PK and PD of single ascending doses of CC-99677 have been reported [23]. The results from the MAD portion of the study are reported here. Thirty-seven healthy adults (67.6% male, 32.4% female, 89.2% white) with an average age of 34 years (range 20–55) and average body mass index of 26.08 kg/m² (range 20–33) completed the once-daily multiple-dosing study. Aside from a slight gender imbalance, demographics were comparable between subjects dosed with CC-99677 and those with placebo (Additional file 1: Table S1).

After 14 consecutive days of dosing, no serious treatment-emergent adverse events (TEAEs) were observed in any of the 37 subjects among the 5 dose-level cohorts ranging from 10 to 150 mg of CC-99677. No subject discontinued the MAD study because of safety reasons. All TEAEs in the MAD study were graded by the investigator as mild (grade 1) according to the FDA toxicity grading scale [26]. The complete TEAE listing is shown in Table 1. TEAEs occurred in 77.8% of subjects receiving placebo compared with 46.4% of subjects receiving CC-99677 (Table 1; Fig. S1A). There was no apparent CC-99677 dose dependency observed with respect to the incidence of TEAEs (Table 1; Fig. S1B). The most commonly reported TEAE was mild headache (n = 5), followed by mild myalgia (n = 3) (Table 1; Fig. S1C). Causality assessment was performed in a blinded fashion; the suspected relationship of TEAE
Fig. 3  CC-99677 inhibited the cytokine production in monocytes and macrophages and reduced the TTP expression through inhibition of MK2. Human monocytes (n = 3) were isolated from the whole blood and were differentiated into macrophages using M-CSF followed by IFNγ. Both monocytes and macrophages were treated with the depicted micromolar concentrations of CC-99677 for 1 h, and the cytokines shown were analyzed after stimulation with 100 ng/mL LPS for 4 or 24 h (a). Lysates from macrophages pretreated with CC-99677 followed by LPS stimulation for 4 h or 24 h were analyzed by capillary electrophoresis and probed with total TTP antibody and GAPDH antibody (b). TNF, IL-6, and IL-1β transcripts were measured at depicted times in macrophages stimulated with LPS and then treated with actinomycin D in the presence of CC-99677 or DMSO (c). Act D, actinomycin D; AUC, area under the curve; DMSO, dimethylsulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; IFNγ, interferon gamma; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimulating factor; MK2, mitogen-activated protein kinase-activated protein kinase-2; TNF, tumor necrosis factor; TTP, tristetraprolin
to study drug, as assessed by the investigator, showed that the majority (69%) of AEs were not suspected to be related to CC-99677 (Fig. S1D). There were no trends among the AEs suspected of relationship to the study drug.

**CC-99677 exhibited a linear and predictable PK profile**
The multiple-dose PK characteristics of CC-99677 showed a linear, dose-proportional increase in concentration and exposure from 10 to 150 mg with a once-daily dosing schedule over 14 days. The geometric mean peak concentration ($C_{max}$, CV%) on day 1 was 20.5 (51.4%), 63.4 (22.1%), 150 (66.4%), 269 (44.7%), and 257 (37.1%) ng/mL, at 10, 30, 60, 120, and 150 mg, respectively. At all 5 dose levels, the PK profile showed minimal detectable plasma CC-99677 > 24 h after dosing, which indicates limited to no day-to-day plasma accumulation of CC-99677 [23]. In line with this finding, no significant difference was observed between (1) dosing day 1 peak or total exposure and (2) peak and total exposure when target engagement steady-state was achieved [32]. The geometric mean $C_{max}$ at the 150-mg dose level corresponds to approximately the 0.8 μM concentration of CC-99677. This concentration falls in the range where significant inhibition of TNF and other cytokines was seen in preclinical in vitro assays.

**MK2 target engagement in PBMCs of healthy volunteers dosed with CC-99677**
The SMaSh assay, which differentiated the levels of free MK2 and CC-99677-bound MK2, demonstrated time- and dose-dependent covalent binding of CC-99677 in lysates of PBMCs from healthy volunteers dosed orally with CC-99677 (Fig. 5). CC-99677 demonstrated dose-dependent increases in MK2 occupancy between 10 and 120 mg, with a plateau at the 120- and 150-mg dose levels. The average MK2 occupancy increased from 28% at day 8 in the 10-mg dose cohort to approximately 70% in the 120- and 150-mg dose cohorts (Fig. 5). MK2 occupancy by CC-99677 was stable until day 15 (1 day after the last dose) and returned to baseline levels 14 days after the last dose.

Having demonstrated a cumulative increase in target engagement with daily dosing, we sought to evaluate the effect on cytokine production in ex vivo peripheral blood stimulation assays. To ensure that cytokine changes were not potentially due to changes in peripheral blood cell numbers induced by dosing with CC-99677, we compared total leukocyte, monocyte, lymphocyte, and neutrophil counts between active and placebo cohorts. Total white blood cell (WBC), lymphocyte, monocyte, and neutrophil counts were monitored from pre-dose baseline through the 14-day daily dosing period. At 150 mg CC-99677, where > 70% MK2 target engagement was observed, the mean (standard deviation [SD]) WBC, lymphocyte, monocyte, and neutrophil counts were comparable to placebo, and no subject had an absolute neutrophil count (ANC) diagnostic of neutropenia (ANC < 1.5 × 10^9 cells/L) (Fig. 6 A–D).
### Table 1  Treatment-emergent adverse events by system organ class

| Treatment-emergent AE, n (%) | CC-99677 10 mg (n = 5) | CC-99677 30 mg (n = 6) | CC-99677 60 mg (n = 6) | CC-99677 120 mg (n = 6) | CC-99677 150 mg (n = 5) | Placebo (n = 9) |
|------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|----------------|
| Subjects with ≥ 1 treatment-emergent AE | 3 (60.0) | 4 (66.7) | 1 (16.7) | 3 (50.0) | 2 (40.0) | 7 (77.8) |
| Nervous system disorders | 2 (40.0) | 1 (16.7) | 1 (16.7) | 1 (16.7) | 0 | 1 (11.1) |
| Headache | 2 (40.0) | 0 | 1 (16.7) | 1 (16.7) | 0 | 1 (11.1) |
| Dizziness | 1 (20.0) | 1 (16.7) | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders | 2 (40.0) | 2 (33.3) | 0 | 1 (16.7) | 0 | 2 (22.2) |
| Nausea | 2 (40.0) | 0 | 0 | 0 | 0 | 0 |
| Constipation | 0 | 0 | 0 | 0 | 0 | 2 (22.2) |
| Diarrhea | 0 | 0 | 0 | 1 (16.7) | 0 | 0 |
| Abdominal pain | 0 | 0 | 0 | 1 (16.7) | 0 | 0 |
| Chapped lips | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Dyspepsia | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Rectal hemorrhage | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 0 | 2 (33.3) | 0 | 1 (16.7) | 0 | 2 (22.2) |
| Back pain | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Myalgia | 0 | 2 (33.3) | 0 | 0 | 0 | 1 (11.1) |
| Musculoskeletal pain | 0 | 0 | 0 | 1 (16.7) | 0 | 0 |
| Infections and infestations | 1 (20.0) | 1 (16.7) | 0 | 0 | 0 | 1 (11.1) |
| Nasopharyngitis | 0 | 1 (16.7) | 0 | 0 | 0 | 1 (11.1) |
| Rash pustular | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions | 2 (40.0) | 0 | 0 | 0 | 0 | 2 (22.2) |
| Vessel puncture site pain | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Catheter site related reaction | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Sensation of foreign body | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Vessel puncture site reaction | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Respiratory, thoracic, and mediastinal disorders | 1 (20.0) | 0 | 0 | 1 (16.7) | 0 | 0 |
| Oropharyngeal pain | 1 (20.0) | 0 | 0 | 1 (16.7) | 0 | 0 |
| Injury, poisoning, and procedural complications | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Muscle strain | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Investigations | 0 | 0 | 0 | 1 (16.7) | 1 (20.0) | 0 |
| Alanine aminotransferase increased | 0 | 0 | 0 | 1 (16.7) | 0 | 0 |
| Aspartate aminotransferase increased | 0 | 0 | 0 | 0 | 1 (20.0) | 0 |
| Blood creatine phosphokinase increased | 0 | 0 | 0 | 0 | 1 (20.0) | 0 |
| Vascular disorders | 0 | 0 | 0 | 0 | 1 (20.0) | 1 (11.1) |
| Flushing | 0 | 0 | 0 | 0 | 1 (20.0) | 0 |
| Hot flush | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Ear and labyrinth disorders | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Ear pain | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Psychiatric disorders | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Insomnia | 1 (20.0) | 0 | 0 | 0 | 0 | 0 |
| Reproductive system and breast disorders | 0 | 0 | 0 | 0 | 1 (20.0) | 0 |
| Dysmenorrhea | 0 | 0 | 0 | 0 | 1 (20.0) | 0 |

AE: adverse event

*Occurred in the same individual 14 days after the end of dosing following greater-than-usual physical activity by the individual*
CC-99677 administration results in sustained inhibition of ex vivo LPS-stimulated cytokine production in healthy volunteers

CC-99677 inhibited TNF at all doses > 10 mg, and this inhibition was sustained until day 14 (Fig. 7A). TNF production was reduced as early as day 2 in the 60-, 120-, and 150-mg dose cohorts. Maximal TNF inhibition was 70% in the 150-mg dose cohort and was consistently maintained at approximately 70% during the dosing period (Fig. 7B). Other cytokines and chemokines were inhibited by CC-99677, but more variability was observed compared with TNF inhibition. Macrophage inflammatory protein (MIP)-1α and MIP-1β were inhibited with continuous dosing at 120 and 150 mg (Fig. 7 C, D). IL-6 production in particular demonstrated marked variability, which may reflect diurnal effects on IL-6 levels [33]. Despite this variability, IL-6 was clearly inhibited at the 150-mg dose level (Fig. 7E). Maximal inhibition of 50% was observed for IL-6 and MIP-1α in the 150-mg dose level cohort at day 5.

**Discussion**

Inhibitors of p38 kinases have been explored as potential anti-inflammatory therapies, but their development was hindered by unfavorable safety profiles and evidence of tachyphylaxis [5, 9]. We have characterized the inhibitory profile of CC-99677 in PBMCs from patients with AS that were stimulated with LPS or SEB/IL-2 to assess the effect of MK2 inhibition in innate and adaptive immune cells in vitro. LPS stimulation of PBMCs focuses on assessing myeloid responses, whereas SEB stimulation focuses on the response elicited from antigen-presenting cells (APCs) and T-cells by binding to class II major histocompatibility complex proteins on APCs and T-cell receptors at the variable region of the β-chain [34]. CC-99677 inhibited TNF and GM-CSF in LPS-stimulated PBMCs and TNF, IL-6, IL-17A, and MCP-1 in SEB/IL-2-stimulated PBMCs. CC-99677 showed strong concentration-dependent inhibition of TNF, IL-6, and IL-1β cytokine production in M1-polarized macrophages and similar, albeit slightly less potent, effects in monocytes. The inhibition of IL-1β in macrophages and monocytes contrasts with the observation in PBMCs, where no inhibition of IL-1β was observed after LPS stimulation, suggesting pro-inflammatory macrophages derived from monocytes with M-CSF and IFNγ treatment have increased sensitivity to MK2 inhibition following LPS stimulation [23].

The constellation of cytokines and chemokines inhibited by CC-99677 may have translational relevance to inflammatory diseases including AS. TNF and IL-17A blockade are efficacious in the treatment of AS [2]. Circulating IL-6 levels are increased in patients with active AS, correlate with disease activity, and may predict treatment response to TNF inhibition [35, 36]. MCP-1 is elevated in the serum of patients with AS and may distinguish patients with mechanical low back pain from AS; furthermore, expression of MCP-1 and its receptor CC chemokine receptor 2 is increased in synovial samples from patients with AS [37, 38]. Additionally, the inhibitory effect in macrophages suggests that CC-99677...
may be effective in suppressing inflammation in an inflamed environment where a significant proportion of pro-inflammatory cytokines are secreted by M-1 type macrophages [39]. Macrophages have been identified as predominant inflammatory cell types infiltrating enthesal sites in AS patient samples [40]. This supports the idea that CC-99677 may be effective in inflammatory diseases, such as AS, for which biologics against TNF and IL-17 have shown efficacy and are approved therapeutic agents [41].

The expression of TNF and other cytokines is controlled at the post-transcriptional level by the p38/MK2 pathway via TTP [17]. MK2 phosphorylates TTP at S52 and S178 after LPS stimulation and increases its stability [20]. As expected, MK2 inhibition resulted in reduced TTP phosphorylation, as reflected by reduced TTP abundance, in LPS-stimulated macrophages. Unphosphorylated TTP recruits deadenylases to ARE-containing cytokine mRNAs [19]. Indeed, actinomycin D treatment in our study demonstrated that CC-99677-mediated inhibition of TTP phosphorylation results in increased decay of cytokine mRNAs. These results support the mechanism of CC-99677 as an MK2 inhibitor that blocks cytokine production through stimulation of TTP-mediated ARE-containing cytokine mRNA decay. Future studies will explore the effect of CC-99677 on TTP-mediated translational repression.

Tachyphylaxis has been a consistent finding in clinical trials of multiple p38 inhibitors. Initial reductions in inflammatory markers were not sustained despite continuous dosing with p38 inhibitors [5, 7, 9, 10]. We generated a novel in vitro model of tachyphylaxis mimicking continuous exposure in an in vitro setting in THP-1 cells. This model was employed to determine the potential for tachyphylaxis with CC-99677 and to compare with p38 inhibitors. CC-99677, but not the p38 inhibitors BMS-582949, BIRB-796, and SCIO-469, consistently inhibited TNF secretion in THP-1 cells over the 14-day assay, suggesting feedback pathways may exist that prevent p38, but not MK2 inhibitors, from demonstrating

![Fig. 6](image-url)
sustained inhibition. While the mechanism of this difference is not yet understood, prior studies in THP-1 cells, macrophages, and synoviocytes have demonstrated the activation of c-Jun N-terminal kinase (JNK) upon treatment with the p38 inhibitors SB203580 and VX-745, but not with the MK2 inhibitor PH089 [12, 13]. In addition,
p38 inhibition has been reported to disrupt the negative feedback by DUSP1, a phosphatase that is activated by p38 phosphorylation and dephosphorylates JNK [42]. p38 inhibitors are also reported to increase the activation of JNK by preventing the phosphorylation of TAK1 binding proteins (TAB1) and prolonging TAK1 activity [43]. Thus, tachyphylaxis observed with p38 inhibitors may be attributed to the disruption of the negative feedback exerted by p38 in controlling inflammatory responses. Future studies will address the differential effects of MK2 inhibition on these feedback pathways.

CC-99677 was well-tolerated with a once-daily oral dosing regimen over 2 weeks in healthy adult volunteers, with all AEs being mild in nature and the majority not suspected of relationship to CC-99677; these observations are similar to the well-tolerated FIH profiles seen with other MK2 inhibitors [44–46]. Despite sustained covalent binding of MK2, multi-cytokine inhibition by CC-99677 does not appear to be a cause or effect of a decrease in peripheral blood WBC or WBC subsets. The lack of neutropenia following 2 weeks of dosing with CC-99677 is encouraging given the mechanism of CC-99677 in inhibiting GM-CSF, TNF, and IL-6 production, as GM-CSF is important in stem cell differentiation into neutrophils, and both TNF and IL-6 blockade are associated with dose-dependent neutropenia [47, 48]. Nonetheless, larger studies in patients will need to confirm the initial safety profile presented here; a phase II study has been initiated in patients with AS (NCT04947579) to measure the safety and efficacy.

As expected for an irreversible covalent inhibitor, MK2 occupancy by CC-99677 accumulated over time with daily dosing, reaching a dose-dependent steady state between days 5 and 8. Pharmacodynamic effects of CC-99677 showed a dose-dependent relationship with ex vivo cytokine inhibition. Of importance, CC-99677 inhibition of TNF was sustained throughout the 14-day treatment period, which contrasts with the reported loss of effect of a p38 inhibitor, BCT197, utilizing a similar assay and clinical study design. Of interest, another MK2 inhibitor, ATI-450 (formerly CDD-450), showed inhibition of LPS-induced TNF for up to 4 weeks after dosing in a mouse model of neonatal-onset multisystem inflammatory disease (NOMID), whereas the global p38a inhibitor CDD-111 (also known as SD-0006) did not [49]. Overall, these lines of evidence suggest that MK2 inhibition may bypass the feedback pathways, which, when elicited by p38 inhibition, result in the tachyphylaxis and transient efficacy that have impeded the clinical development of p38 inhibitors. However, clinical evaluation in longer studies in a disease setting is necessary to confirm these findings.

As the experiments and FIH study were in vitro and ex vivo assessments, these findings cannot be fully extrapolated to results in patients with endogenously elevated pro-inflammatory cytokine levels. Phase II and III studies in large patient cohorts will be needed to confirm the findings suggested by the FIH experience. Nevertheless, the effects of CC-99677 were consistent across different experimental conditions, and the in vitro and ex vivo assays were replicable.

While the period between the late 1990s and mid-2010s was dominated by a brave new world of biologic proteins targeting single cytokines or their related receptors, recent drug discovery and development in rheumatology, dermatology, and other inflammatory diseases have been marked by small-molecule, multi-cytokine inhibitors. These approaches may offer improved efficacy and convenience. Inhibition of the JAK-STAT pathway, for example, has emerged as a viable treatment regimen for several conditions including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease [50]. Promising phase III data are also emerging in AS [51]. However, some safety liabilities exist for JAK inhibitors, with an increased risk of serious infections and a higher incidence of venous thromboembolic events; therefore, alternatives are desired [52]. As prescribers and patients move toward a preference for safe and effective oral options as opposed to injectable or infusible treatments, once-daily, oral, multi-cytokine inhibition with CC-99677 as a monotherapy or in combination with other oral agents holds promise for an era of new treatment paradigms. The observed lack of tachyphylaxis in in vitro and ex vivo assays of human cells exposed to CC-99677, compared with disappointing earlier attempts to target the p38 axis [7, 53], are encouraging findings and suggest that MK2 inhibition may prevail where direct p38 inhibition has historically failed.

**Conclusions**

The results of the FIH study, as well as characterization of CC-99677 in vitro and ex vivo, show that inhibition of MK2 potently reduces inflammatory cytokines and chemokines relevant to the pathophysiology of AS. The CC-99677 safety and tolerability profile, linear PK profiles, and a high degree of target engagement resulting in sustained inhibition of inflammatory disease-relevant cytokines ex vivo suggest that further investigation of the therapeutic potential of CC-99677 in future clinical studies is worthwhile.

**Abbreviations**

AE: Adverse event; ANC: Absolute neutrophil count; ANOVA: Analysis of variance; APC: Antigen-presenting cells; ARE: AU-rich elements; AS: Ankylosing spondylitis; ATM: Tumor necrosis factor-α; Cmax: Peak concentration; CRP: C-reactive protein; DMSO: Dimethyl sulfoxide; DUSP1: Dual-specificity phosphatase 1; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HuR: Human antigen R; IFN: Interferon; IL: Interleukin; JAK: Janus kinase; JNK: Jun N-terminal kinase; JAK1: Janus kinase 1; JAK2: Janus kinase 2; JAK3: Janus kinase 3; JME: Juvenile multifocal evanescent myelitis; JMD: Juvenile myeloneuropathy; JNSY: Juvenile non-specific encephalomyelitis; JPS: Juvenile periodic syndrome; JSD: Juvenile spondyloarthropathy; LPS: Lipopolysaccharide; MFI: Mean fluorescence intensity; MLR: Mixed leukocyte reaction; MPO: Myeloperoxidase; NOS: Nitric oxide synthase; NRM: Normal renal myelitis; OAD: Oral anticoagulant drug; OP: Oral prednisolone; OSE: Oral steroid equivalent; PDE: Phosphodiesterase; PLA2: Phospholipase A2; PR: Primary; RA: Rheumatoid arthritis; REG: Relative efficacy gain; RHE: Relapsing hereditary epistaxis; RN: Reference neutrophil; SAA: Serum amyloid A; SCD: Systemic childhood dermatitis; SD: Steady state; sIL-6R: Soluble IL-6R; sTNF: Soluble TNF; TD: Targeted drug; TNF: Tumor necrosis factor; T10: T10 synovitis; TOF: Total oral fluid; UCB: Umbilical cord blood; VCAM: Vascular cell adhesion molecule; VEGF: Vascular endothelial growth factor; WBC: White blood cell; WNV: West Nile virus; XPA: Xeroderma pigmentosum group A; ZIKV: Zika virus; ZD: Zoonotic disease; ZS: Zoonotic spondylitis; ZV: Zoonotic vasculitis
kinase; LPS: Lipopolysaccharide; MAPK: Mitogen-activated protein kinase; MAD: Multiple ascending dose; MCP-1: Monocyte chemoattractant protein-1; MIP: Macrophage inflammatory protein; MKK4/7: MAPK kinase 4/7; MK2: Mitogen-activated protein kinase-activated protein kinase-2; PBMC: Peripheral blood mononuclear cell; PD: Pharmacodynamics; PK: Pharmacokinetics; PBS: Phosphate-buffered saline; SD: Standard deviation; SEB: Staphylococcal enterotoxin-B; SmaSh: Streptavidin mass shift; TAb1: TAK1-binding proteins; TEAE: Treatment-emergent adverse events; TTP: Tristetraprolin; TNF: Tumor necrosis factor; UTR: Untranslated regions; WBC: White blood cell.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02850-6.

Additional file 1: Table S1. Demographics. Figure S1. Multiple daily doses of CC-99677 were well tolerated in healthy volunteers. Proportion of active CC-99677 (n = 28) or placebo (n = 9) subjects with or without TEAEs (a). Number of TEAEs by dose level of CC-99677 and among placebo group (b). Frequency of TEAEs by MedDRA preferred term in the system organ classes in which at least 3 subjects receiving CC-99677 experienced an AE (c). The MedDRA system organ classes in which these AEs are grouped are: "nervous system disorders" (n = 5 active subjects), "gastrointestinal disorder" (n = 5 active subjects), and "musculoskeletal and connective tissue disorders" (n = 3 active subjects). Proportion of subjects with TEAEs by suspected relationship to CC-99677 by blinded investigator (n = 13 active subjects experiencing AEs) (d). TEAE treatment-emergent adverse event, MedDRA Medical Dictionary for Regulatory Activities.

Acknowledgements

We would like to acknowledge the healthy volunteers who participated in the clinical trial. We would like to thank Steven Greenberg, MD, Elena Kostenko, PhD, Phillip Sherratt, PhD, and Liangang Liu, PhD, for reviewing the manuscript and providing guidance. Writing and editorial assistance were provided by Amy Zannikos, PharmD, of Peloton Advantage, LLC, an OPEN Health company, funded by Bristol Myers Squibb.

Authors' contributions

FRV, KAM, and SM designed the clinical trial. SM was the clinical study investigator. KAM enrolled the patients. RG, KAM, and FRV prepared the manuscript. All authors contributed to the collection, assembly, analysis, and interpretation of the data and contributed to and approved the final manuscript.

Funding

This study was supported by Bristol Myers Squibb.

Availability of data and materials

Bristol Myers Squibb’s policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html.

Declarations

Ethics approval and consent to participate

The clinical study protocol, informed consent document, and other study-related documents were reviewed and approved by the London-Riverside Ethics Committee (independent ethics committee) and the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). The study was conducted in compliance with the Declaration of Helsinki, International Council for Harmonisation Guideline for Good Clinical Practice, and applicable regional and country regulatory requirements.

Consent for publication

All study subjects provided written informed consent prior to the start of any study-specific procedures.

Competing interests

RG, KM, JS, MA, SP, MT, GH, PS, and FRV are employees of and shareholders in Bristol Myers Squibb. SM is an employee of and shareholder in Quotient Sciences.

Author details

Bristol Myers Squibb, Princeton, NJ, USA. 2 Quotient Sciences, Nottingham, UK.

Received: 16 December 2021 Accepted: 13 June 2022

Published online: 18 August 2022

References

1. Reveille JD, Arnett FC. Spondyloarthropathy: update on pathogenesis and management. Am J Med. 2005;118(6):592–603.

2. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthropathy Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthropathy. Arthritis Care Res (Hoboken). 2019;71(10):1285–99.

3. Braun J, Haibel H, de Hooge M, Landewe R, Rudwaleit M, Fox T, et al. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Res Ther. 2019;21(1):142.

4. Baraliakos X, Gensler LS, D’Angelo S, Iannone F, Favaelli EG, de Peyrecave N, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review. Ther Adv Musculoskelet Dis. 2020;12:1759720X20906040.

5. Damjanov N, Kaufman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60(5):1232–41.

6. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha/alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010;53(6):2345–53.

7. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009;60(2):317–20.

8. Han J, Wu J, Silke J. An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling. F1000Res. 2020;9(F1000 Faculty Rev):653.

9. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis: J Rheumatol. 2011;38(5):846–54.

10. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamipamod, a p38 MAPK inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(2):335–44.

11. Schreiber S, Feagan B, D’Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(3):325–34.

12. Dukus J, Wijnands FP, van den Hurk-van Aalbeek JA, van Vugt MJ, Rul-Imann JA, Schot JJ, et al. P38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Rheumatol. 2013;31(4):515–25.

13. Muniyappa H, Das KC. Activation of c-Jun N-terminal kinase (JNK) by p38 MAPK and MK2: a common mechanism? eLife. 2016;5:e14025.

14. He et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem. 2002;277(5):3065–8.

15. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999;1(2):94–7.

16. Hitti E, Jakubovska T, Brock M, Deppe-Meier S, Gruber AD, Radzioch D, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering...
tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol. 2006;26(16):2399–407.

17. Tiedje C, Ronkina N, Tehrani M, Dhamija S, Laas K, Holtmann H, et al. The p38/MK2-driven exchange between tristetraprolin and HIF regulates AU-rich element-dependent translation. PLoS Genet. 2012;8(9):e1002977.

18. Brooks SA, Connolly JE, Rigby WF. The role of tRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J Immunol. 2004;172(2):7263–71.

19. Clement SL, Scheckel C, Stoecklin G, Lykke-Andersen J. Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment. Mol Cell Biol. 2011;31(2):256–66.

20. Ronkina N, Shushakova N, Tiedje C, Yakovleva T, Tollenaere MA, Scott A, et al. The role of TTP phosphorylation in the regulation of inflammatory cytokine production by MK2/3. J Immunol. 2019;203(8):2291–300.

21. Heigen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Tellez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol. 2006;177(3):1913–7.

22. Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010;333(3):797–807.

23. Malona J, Chuaqui C, Seletsky BM, Beebe L, Cantin S, van Kalken D, et al. Discovery of CC-96677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders. Transl Res. 2022;219:235–44(22).doi:10.138.4.

24. https://doi.org/10.1161/trial202200136. (Online ahead of print).

25. Menish K, Gaur R, Connolly J, Thomas M, Liu M, Mair S, et al. CC-96677: a novel, oral, selective MK2 inhibitor with sustainable multi-cytokine inhibition for the treatment of ankylosing spondylitis and other inflammatory arthritides. Arthritis Rheumatol. 2021;73(8):10489.

26. Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy testing in clinical trials. 2014. https://www.hmaeurope/fileadmin/dateien/Human_Medicines/01_About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. Accessed December 3, 2020.

27. U.S. Food and Drug Administration. Guidance for industry: Toxicology grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. https://www.fda.gov/media/73679/download. Accessed December 15, 2021.

28. Labenski MT, Batenova LA, Voortman LT, Giammo G, Cotton S, Qiao L, et al. SMAsh: a streptavidin mass shift assay for rapidly quantifying target occupancy by reversible inhibitors. Biochemistry. 2021;60(39):2915–24.

29. Al-Mossawi MH, Chen L, Fang H, Ridley A, de Wit J, Vager N, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017;8(1):1510.

30. Shi H, Chen L, Ridley A, Zuurour N, Brough I, Caucci C, et al. GM-CSF primes proinflammatory monocyte responses in ankylosing spondylitis. Front Immunol. 2020;11:520.

31. Wright C, Edeleman M, D’elioja K, Kolbnerberger S, Kramer H, McGowen S, et al. Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the ubiquitin proteasome pathway. Ann Rheum Dis. 2009;68(10):1626–32.

32. Conrad K, Wu P, Sieper J, Sybre U. In vivo pre-activation of monocytes in patients with axial spondyloarthritis. Arthritis Res Ther. 2015;17(1):179.

33. Connam JN, Gaur R, Ramirez-Valle F, Mensah KA, Thomas M, Palmasano M, et al. Approval PK/PD analysis for a novel MK2 inhibitor (MK20). Clin Pharmacol Ther. 2020;107(5):539.

34. Nilsson G, Lekander M, Åkerstedt T, Axelsson J, Ingre M. Diurnal variation of circulatory interleukin-23 in humans: a meta-analysis. PLoS One. 2016;11(11):e0165799.

35. Dong Y, Guo J, Li B. Baseline interleukin-6 and erythrocyte sedimentation rate can predict clinical response of TNF-inhibitor treatment in patients with ankylosing spondylitis. Ann Clin Lab Sci. 2019;49(5):611–8.

36. Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D, et al. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther. 2016;18(1):304.

37. Ciccia F, Guggino G, Zeng M, Thomas R, Ranganathan V, Rahman A, et al. Proinflammatory CX3CR1+CD59+ tumor necrosis factor-like molecule 1A+ interleukin-23+ monocytes are expanded in patients with ankylosing spondylitis and modulate innate lymphoid cell 3 immune functions. Arthritis Rheumatol. 2018;70(12):2003–13.

38. Romero-Sanchez C, Tsou HK, Jan MS, Wong RH, Chang IC, Londoño J, et al. Serum monocyte chemotactic protein-1 concentrations distinguish patients with ankylosing spondylitis from patients with mechanical low back pain. J Spinal Disord Tech. 2011;24(3):202–7.

39. Tarique AA, Logan J, Thomas E, Holt PG, Sly PD, Fantino E. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53(5):676–88.

40. McGonagle D, Marzo-Ortega H, O’Connor P, Gibbon W, Hawkey P, Henshaw K, et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis. 2002;61(6):534–7.

41. Podobrubny D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology (Oxford). 2018;57(7):1145–50.

42. Staples CJ, Owens DM, Maer JV, Cato AC, Keyse SM. Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation. J Biol Chem. 2010;285(34):25929–30.

43. Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J. 2003;22(11):579–803.

44. Schnyder J, Monahan J, Smith W, Hope H, Kelly D, Burt D, et al. A phase 1 study in healthy volunteers exploring the safety, pharmacokinetics and pharmacodynamics of AT1-450; a novel oral MK2 inhibitor [abstract SAT0143]. Ann Rheum Dis. 2020;79(suppl 1):1006.

45. Luber A, Peterson C, Panitch A, Wetering JVD, Hoogdaelem EV, Nicholson G, et al. MMI-0100, a novel MAPK kinase II (MK2) inhibitor, delivered via inhalation, displays an excellent safety and tolerability profile in three phase 1 clinical trials [abstract]. Am J Resp Crit Care Med. 2020;201:A7468.

46. Gordon D, Hellriegel ET, Hope HR, Burt D, Monahan JB. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the MK2 inhibitor AT1-450 in healthy subjects: a placebo-controlled, randomized phase 1 study. Clin Pharmacol. 2021;13:123–34.

47. Dillingh NR, Reijen JA, Malone K, Burringa J, Bahrt K, Yamashita L, et al. Clinical evaluation of Humira® biosimilar ONS-3010 in healthy volunteers: focus on pharmacokinetics and pharmacodynamics. Front Immunol. 2016;7:508.

48. Shovman O, Shoenfeld Y. Tocilizumab-induced neutropenia: analysis of a phase 3 randomized, double-blind, placebo-controlled study [abstract L11]. Arthritis Rheumatol. 2020;72(suppl 10):Abstract number 0489.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.